

DOASENSE announces new partnership with SUNMEDCARE as appointed exclusive distributor for Brazil

HEIDELBERG – 30 November 2020 – DOASENSE GmbH, an in vitro diagnostics company focused on the development and commercialization of innovative rapid tests, today announced that SUNMEDCARE has been appointed as exclusive distributors of DOASENSE solutions in Brazil.

We are delighted to announce a new partnership with SUNMEDCARE, as our exclusive distributor for Brazil. SUNMEDCARE's successful track record introducing new point-of-care tests in Brazil makes them the ideal partner for a market where the number of DOAC patients and therefore the need of testing is growing rapidly. The DOASENSE DOAC Dipstick remains the only approved DOAC rapid test available on the market.

"We are excited with the new and innovative solution offered by DOASENSE. It is a perfect fit to our portfolio of diagnostic solutions, always aiming at better and faster clinical decisions for our customers and a goal directed therapy" said Ricardo Chamas, Managing Director at SUNMEDCARE.

The agreement is effective immediately.

Information about DOASENSE solutions in Brazil is available from

administracao@sunmedcare.com.br

About the DOASENSE Product Suite:

The CE-marked and TGA registered DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

About DOASENSE:

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE's exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need.

The company is open to distributor inquiries for further broadening the international market presence of its products.

Contact:

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany

info@doasense.de

www.doasense.de